中文名称 | 奎扎替尼 |
---|---|
英文名称 | Quizartinib (Synonyms: AC220; AC708) |
CAS号 | 950769-58-1 |
分子式 | C29H32N6O4S |
分子量 | 560.67 |
外观 | White to off-white powder |
储存条件 | Dry, dark and at 0 - 4 ℃ for short term (days to weeks) or -20 ℃ for long term (months to years). |
Quizartinib (formerly also know as AC-220; AC-010220, Vanflyta) is a novel, potent, 2nd-generation, and orally bioavailable FLT3 tyrosine kinase inhibitor for Flt3 (ITD/WT) with potential anticancer activity.With IC50s of 1.1 nM and 4.2 nM, respectively, it inhibits FLT3 in MV4-11 and RS4EL11 cells. With respect to KIT, PDGFRα, PDGFRβ, RET, and CSF-1R, it demonstrates a ten-fold greater selectivity. Currently, Daiichi Sankyo is developing quizartinib to treat acute myeloid leukemia. Quizartinib (Vanflyta) was approved in 2023 by FDA for treating AML.
Keywords: buy Quizartinib (AC220) | Quizartinib (AC220) ic50 | Quizartinib (AC220) price | Quizartinib (AC220) cost | Quizartinib (AC220) solubility dmso | Quizartinib (AC220) purchase | Quizartinib (AC220) manufacturer | Quizartinib (AC220) research buy | Quizartinib (AC220) order | Quizartinib (AC220) mouse | Quizartinib (AC220) chemical structure | Quizartinib (AC220) mw | Quizartinib (AC220) molecular weight | Quizartinib (AC220) datasheet | Quizartinib (AC220) supplier | Quizartinib (AC220) in vitro | Quizartinib (AC220) cell line | Quizartinib (AC220) concentration | Quizartinib (AC220) nmr
© 2020-2024 凯立德生物医药技术(上海)有限公司 版权所有
沪ICP备15046197号-3
沪公网安备31011502007856号
Designed by Kuanersoft